Healthtech Solutions Inc. (HLTT) Initiates Incubator Model to Develop Powerful Biotech and Medtech Portfolio
- Providing invaluable support to promising startups sets HLTT apart as early-stage companies work to break with tradition, launch their own products
- Playing a strategic role during critical phases of company life-cycles is a key approach that Healthtech is confident will breed increased chances of success
- VarianBio joins MediScan, RevHeart as trio of innovative healthcare technology companies in HLTT portfolio
A new trend is emerging in the world of drug development — a trend that Healthtech Solutions (OTC: HLTT) is intent on leveraging as it focuses on developing a strong portfolio model in biotech and medtech. That commitment to reinventing the incubator model and providing invaluable support to promising startups sets HLTT apart as companies work to break with tradition and launch their own products.
“Imagine you’re the leader of a small biopharmaceutical company,” a recent McKinsey & Company article stated. “As your new drug makes good progress through clinical trials, you face a moment of truth: Do you have what it takes to launch your product yourself? Twenty years ago, the answer to that question would almost certainly have been ‘no.’ Small biotechnology and biopharma companies followed a well-worn path for their assets and explored licensing, partnership, and outright acquisition as their means to product launches. But that pattern has shifted over the past decade or so as more small companies decide to launch their products themselves.
“Globally, those first-time launchers account for more than a quarter of all new molecular entities submitted to the US FDA since 2016,” the article pointed out. “That share rises to more than a third when including subsequent launches from companies that launched their first product after 2001.”
Being a key piece of these first-time launchers in the pharmaceutical industry is a strategic approach that Healthtech is confident will bring success. Most recently, HLTT broadened its portfolio and entered the precision cancer care market when it acquired VarianBio, a company that is developing two preclinical assets: VAR-101 for basal cell carcinoma (“BCC”) and VAR-102 for a variety of solid tumors, including pancreatic, colorectal and NSCLC. VarianBio joins MediScan and RevHeart as a trio of innovative healthcare technology companies benefitting from Healthtech’s commitment to providing experienced leadership, deep insight and valued resources to the biopharmaceuticals space.
“Varian Bio is at the leading edge of cancer treatment technology, and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman David Rubin. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.”
VarianBio is developing a proprietary atypical protein kinase C iota (aPKCI) inhibitor for the treatment of various tumor types. In addition to the strides the company is making in precision oncology, Healthtech is also developing technology to transform 2D images from a portable ultrasound into digital 3D images with AI/ML interpretation to bring accurate decision making to the bedside. The technology, being developed by subsidiary MediScan, has applications in lung, cardiac and musculoskeletal imaging and related uses.
For more information, visit the company’s website at www.HealthTechSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Providing invaluable support to promising startups sets HLTT apart as early-stage companies work to break with tradition, launch their own products
- Playing a strategic role during critical phases of company life-cycles is a key approach that Healthtech is confident will breed increased chances of success
- VarianBio joins MediScan, RevHeart as trio of innovative healthcare technology companies in HLTT portfolio
A new trend is emerging in the world of drug development — a trend that Healthtech Solutions (OTC: HLTT) is intent on leveraging as it focuses on developing a strong portfolio model in biotech and medtech. That commitment to reinventing the incubator model and providing invaluable support to promising startups sets HLTT apart as companies work to break with tradition and launch their own products.
“Imagine you’re the leader of a small biopharmaceutical company,” a recent McKinsey & Company article stated. “As your new drug makes good progress through clinical trials, you face a moment of truth: Do you have what it takes to launch your product yourself? Twenty years ago, the answer to that question would almost certainly have been ‘no.’ Small biotechnology and biopharma companies followed a well-worn path for their assets and explored licensing, partnership, and outright acquisition as their means to product launches. But that pattern has shifted over the past decade or so as more small companies decide to launch their products themselves.
“Globally, those first-time launchers account for more than a quarter of all new molecular entities submitted to the US FDA since 2016,” the article pointed out. “That share rises to more than a third when including subsequent launches from companies that launched their first product after 2001.”
Being a key piece of these first-time launchers in the pharmaceutical industry is a strategic approach that Healthtech is confident will bring success. Most recently, HLTT broadened its portfolio and entered the precision cancer care market when it acquired VarianBio, a company that is developing two preclinical assets: VAR-101 for basal cell carcinoma (“BCC”) and VAR-102 for a variety of solid tumors, including pancreatic, colorectal and NSCLC. VarianBio joins MediScan and RevHeart as a trio of innovative healthcare technology companies benefitting from Healthtech’s commitment to providing experienced leadership, deep insight and valued resources to the biopharmaceuticals space.
“Varian Bio is at the leading edge of cancer treatment technology, and it is an honor to have them join our portfolio,” said Healthtech Solutions chairman David Rubin. “The fact that they are developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is. Precision oncology is an exciting field, and we’re thrilled to be a part of it.”
VarianBio is developing a proprietary atypical protein kinase C iota (aPKCI) inhibitor for the treatment of various tumor types. In addition to the strides the company is making in precision oncology, Healthtech is also developing technology to transform 2D images from a portable ultrasound into digital 3D images with AI/ML interpretation to bring accurate decision making to the bedside. The technology, being developed by subsidiary MediScan, has applications in lung, cardiac and musculoskeletal imaging and related uses.
For more information, visit the company’s website at www.HealthTechSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://nnw.fm/HLTT
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
